Compile Data Set for Download or QSAR
Report error Found 142 Enz. Inhib. hit(s) with all data for entry = 2545
TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370772BDBM370772(US10239835, Example 00324)
Affinity DataIC50: 4.41nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370754BDBM370754(US10239835, Example 00306)
Affinity DataIC50: 4.44nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370814BDBM370814(US10239835, Example 00365)
Affinity DataIC50: 5.24nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370813BDBM370813(US10239835, Example 00364)
Affinity DataIC50: 5.25nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370756BDBM370756(US10239835, Example 00308)
Affinity DataIC50: 5.72nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370745BDBM370745(US10239835, Example 00297)
Affinity DataIC50: 5.96nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370743BDBM370743(US10239835, Example 00295)
Affinity DataIC50: 6.20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370781BDBM370781(US10239835, Example 00333)
Affinity DataIC50: 6.81nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370815BDBM370815(US10239835, Example 00366 | US20240199576, Example...)
Affinity DataIC50: 8.30nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370816BDBM370816(US10239835, Example 00367 | US20240199576, Example...)
Affinity DataIC50: 8.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370769BDBM370769(US10239835, Example 00321)
Affinity DataIC50: 8.62nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370797BDBM370797(US10239835, Example 00349)
Affinity DataIC50: 8.78nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370802BDBM370802(US10239835, Example 00354)
Affinity DataIC50: 9.36nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370768BDBM370768(US10239835, Example 00320)
Affinity DataIC50: 9.60nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370744BDBM370744(US10239835, Example 00296)
Affinity DataIC50: 10.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370676BDBM370676(US10239835, Example 00228)
Affinity DataIC50: 13nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370678BDBM370678(US10239835, Example 00230)
Affinity DataIC50: 14nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370782BDBM370782(US10239835, Example 00334)
Affinity DataIC50: 14.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370755BDBM370755(US10239835, Example 00307)
Affinity DataIC50: 16.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370681BDBM370681(US10239835, Example 00233)
Affinity DataIC50: 17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370727BDBM370727(US10239835, Example 00279)
Affinity DataIC50: 17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370694BDBM370694(US10239835, Example 00246)
Affinity DataIC50: 18nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370809BDBM370809(US10239835, Example 00361)
Affinity DataIC50: 19.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370817BDBM370817(US10239835, Example 00368)
Affinity DataIC50: 20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370812BDBM370812(US10239835, Example 00363)
Affinity DataIC50: 20.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370749BDBM370749(US10239835, Example 00301)
Affinity DataIC50: 20.9nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370757BDBM370757(US10239835, Example 00309)
Affinity DataIC50: 21.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370784BDBM370784(US10239835, Example 00336)
Affinity DataIC50: 23.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370794BDBM370794(US10239835, Example 00346)
Affinity DataIC50: 26.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370801BDBM370801(US10239835, Example 00353)
Affinity DataIC50: 26.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370767BDBM370767(US10239835, Example 00319)
Affinity DataIC50: 29.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370714BDBM370714(US10239835, Example 00266)
Affinity DataIC50: 30.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370722BDBM370722(US10239835, Example 00274)
Affinity DataIC50: 30.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370740BDBM370740(US10239835, Example 00292)
Affinity DataIC50: 37.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370800BDBM370800(US10239835, Example 00352)
Affinity DataIC50: 38nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370765BDBM370765(US10239835, Example 00317)
Affinity DataIC50: 41.1nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370711BDBM370711(US10239835, Example 00263)
Affinity DataIC50: 41.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370698BDBM370698(US10239835, Example 00250)
Affinity DataIC50: 46.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370675BDBM370675(US10239835, Example 00227)
Affinity DataIC50: 47nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370702BDBM370702(US10239835, Example 00254)
Affinity DataIC50: 47.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370787BDBM370787(US10239835, Example 00339)
Affinity DataIC50: 50.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370712BDBM370712(US10239835, Example 00264)
Affinity DataIC50: 51.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370705BDBM370705(US10239835, Example 00257)
Affinity DataIC50: 52.1nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370721BDBM370721(US10239835, Example 00273)
Affinity DataIC50: 53.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370689BDBM370689(US10239835, Example 00241)
Affinity DataIC50: 53.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370758BDBM370758(US10239835, Example 00310)
Affinity DataIC50: 55.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370718BDBM370718(US10239835, Example 00270)
Affinity DataIC50: 57.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370683BDBM370683(US10239835, Example 00235)
Affinity DataIC50: 58.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370799BDBM370799(US10239835, Example 00351)
Affinity DataIC50: 60.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1/2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370677BDBM370677(US10239835, Example 00229)
Affinity DataIC50: 61.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

Displayed 1 to 50 (of 142 total ) | Next | Last >>
Jump to: